Dr. Carlos Doti Explains How AstraZeneca's LYNPARZA Has Changed Oncology

When AstraZeneca’s first PARP inhibitor (PARPi), LYNPARZA® (olaparib), was FDA-approved in 2014, it marked the start of a new era of oncology leadership for the company -- since that approval, eight new AstraZeneca cancer therapies (treating many different types of cancers, including lung, liver, breast and more) have come to market. The company has bold ambitions in cancer care, with goals of treating some of the hardest to treat cancers, many of which have few treatment options.
This year, LYNPARZA, which has been used to treat approximately 140,000 patients worldwide, celebrates 10 years of being on the market.
DocWire News spoke with Carlos Doti, MD, AstraZeneca’s Global Medical Affairs Head, to discuss the scientific innovations behind LYNPARZA throughout the past decade.